Levothyroxine Solvent Composition for Stability and Weekly Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oral levothyroxine treatments for hypothyroidism face challenges such as inadequate absorption in the GI tract, patient non-compliance, and rapid degradation in aqueous solutions, leading to suboptimal TSH control and health complications.
Innovation Solution
Development of stable, non-aqueous formulations using aprotic polar solvents and ionization stabilizing agents to create storage-stable compositions that promote gradual therapeutic release, improving bioavailability and compliance through subcutaneous administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oral levothyroxine is administered daily, then therapeutic effect is maintained, but patient compliance deteriorates due to chronic daily regimen burden
Solution Approach 1:
The patent segments the total weekly therapeutic dose into multiple smaller subcutaneous injection sites, allowing the medication to be administered once weekly rather than daily orally. This segmentation of dosing frequency directly addresses the compliance issue while maintaining therapeutic effectiveness through sustained release from the injection sites.
Solution Approach 2:
The patent changes the administration route from oral to subcutaneous injection and modifies the dosing frequency from daily to once-weekly. This parameter change in administration method and frequency fundamentally improves patient compliance while maintaining or enhancing therapeutic reliability through direct bloodstream delivery and sustained release mechanisms.
2Reliability
If levothyroxine is dissolved in aqueous solution, then bioavailability is improved, but stability deteriorates due to rapid degradation
Solution Approach 1:
The patent changes the solvent parameter from aqueous to non-aqueous (specifically DMSO-based), which fundamentally alters the stability profile of levothyroxine. This parameter change in solvent composition prevents rapid degradation while maintaining solubility and bioavailability, directly resolving the contradiction between stability and bioavailability.
Solution Approach 2:
The patent employs a composite formulation system combining DMSO as the primary solvent with additional excipients and stabilizing agents. This composite material approach creates a synergistic system that provides both the solubility needed for bioavailability and the chemical stability required to prevent degradation, simultaneously addressing both requirements.
3Reliability
If levothyroxine solubility is increased in aqueous formulations, then bioavailability improves, but degradation rate increases
Solution Approach 1:
The patent changes the fundamental solvent parameter from water-based to DMSO-based, which simultaneously achieves high solubility for levothyroxine (improving bioavailability) while creating a chemically inert environment that prevents degradation (extending shelf life). This single parameter change resolves both requirements.
Solution Approach 2:
The patent uses DMSO as an intermediary solvent that mediates between the conflicting requirements of solubility and stability. DMSO acts as a bridge that allows levothyroxine to remain dissolved at therapeutic concentrations without undergoing the degradation pathways that occur in aqueous environments, thereby extending shelf life while maintaining bioavailability.
4Reliability
If oral levothyroxine absorption is enhanced, then TSH control improves, but adverse effects from food and GI comorbidities increase
Solution Approach 1:
The patent extracts the levothyroxine delivery from the gastrointestinal tract environment entirely by using subcutaneous injection as the administration route. This removal of the drug from the GI tract eliminates all harmful interactions with food, enzymes, and comorbidities that currently interfere with absorption, while ensuring reliable TSH control through direct systemic delivery.
Solution Approach 2:
The patent introduces subcutaneous tissue as an intermediary delivery site that bypasses the problematic GI tract environment. This intermediary route of administration allows levothyroxine to enter the bloodstream directly without encountering food, digestive enzymes, or GI comorbidities, thereby eliminating absorption variability and ensuring reliable TSH control.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulations provide extended therapeutic levels, improved solubility, and stability, enhancing patient compliance and reducing health risks associated with daily oral regimens.
Implementation Method 1
by dissolving a therapeutic agent (active pharmaceutical ingredient), such as levothyroxine, in an aprotic polar solvent system to produce stable therapeutic formulations
Implementation Method 2
use of aprotic polar solvents, water, and at least one ionization stabilizing agent to prepare stable therapeutic formulations of a variety of active pharmaceutical ingredients
Data Source
AI summary
The present invention concerns the use of aprotic polar solvents and an ionization stabilizing agent to prepare stable therapeutic formulations of levothyroxine by dissolving levothyroxine in an aprotic polar solvent system that can then be used to treat, prevent, and/or diagnose certain diseases and disorders in humans and veterinary animals by administration of the formulation thereto. In certain embodiments, the invention is directed to formulations comprising levothyroxine, and optionally one or more additional therapeutic agents, dissolved in an aprotic polar solvent system, such as a DMSO/water admixture comprising at least one ionization stabilizing excipient in a concentration sufficient to impart physical and chemical stability to the therapeutic agent. The invention also provides methods of use of such formulations in treating, preventing, and/or diagnosing diseases and disorders, and methods of manufacturing such formulations.